TOKYO, Japan & BASKING RIDGE, NJ, USA I January 17, 2055 I DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of ...
Key Takeaways JNJ will buy Intra-Cellular Therapies, producer of a drug for bipolar disorder, for $14.6 billion. Eli Lilly ...
The "Antibody Drug Conjugates Market Report 2025-2035" has been added to ResearchAndMarkets.com's offering.World revenue for the Antibody Drug Conjugates Market is set to surpass US$16 billion in 2025 ...
Daiichi Sankyo buys solid tumour ADC from Glycotope for $132.5m Daiichi Sankyo has finalised the acquisition of intellectual ...
AstraZeneca and Daiichi Sankyo's Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted and granted Priority Review in the US for the treatment of adult patients ...
AstraZeneca and Daiichi Sankyo's Biologics License Application (BLA) for datopotamab deruxtecan has been accepted by the U.S. FDA for treating ad ...